PMID- 35718679
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221028
IS  - 1477-2574 (Electronic)
IS  - 1365-182X (Linking)
VI  - 24
IP  - 10
DP  - 2022 Oct
TI  - Impact of FGFR2 gene fusions on survival of patients with intrahepatic 
      cholangiocarcinoma following curative intent resection.
PG  - 1748-1756
LID - S1365-182X(22)01486-1 [pii]
LID - 10.1016/j.hpb.2022.05.1341 [doi]
AB  - BACKGROUND: Intrahepatic Cholangiocarcinoma (iCCA) is an aggressive cancer with 
      diverse mutational profiles. An important molecular subtype is fibroblast growth 
      factor receptor 2 (FGFR2) fusion. The effect of FGFR2 fusions on prognosis is 
      unknown. Our aim was to assess the outcomes in resected CCA patients in relation 
      to FGFR2 status. METHODS: Surgically treated CCA patients from a single 
      institution were retrospectively reviewed between 2008 and 2014. FGFR 
      rearrangements were detected by fluorescence in situ hybridization (FISH). Data 
      included patient demographics, tumor pathology, disease-free survival (DFS) and 
      overall survival (OS). RESULTS: Ninety-five patients underwent surgical resection 
      for iCCA. Twelve (13%) of these were found to have FGFR2 fusion, none of which 
      were treated with FGFR targeted therapy. Patients with FGFR2 fusions were found 
      to have a longer 5-year (83 vs. 32%, p = 0.01) and 10-year (46 vs. 22%, p = 0.04) 
      OS. Five and 10-year DFS was also increased (68 vs. 33% p = 0.04) and (68 vs. 25 
      %, p = 0.02,). FGFR2 fusion status was the strongest independent factor 
      associated with improved OS (HR 0.23, 0.09-0.62, p=0.003) and DFS (HR 0.18, 
      0.05-0.67, p=0.01). CONCLUSION: Patients with CCA FGFR2 fusion have improved OS 
      and DFS following surgical resection.
CI  - Copyright (c) 2022 International Hepato-Pancreato-Biliary Association Inc. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Buckarma, EeeLN
AU  - Buckarma E
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - De La Cruz, Gabriel
AU  - De La Cruz G
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Truty, Mark
AU  - Truty M
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Nagorney, David
AU  - Nagorney D
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Cleary, Sean
AU  - Cleary S
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Kendrick, Michael
AU  - Kendrick M
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Borad, Mitesh
AU  - Borad M
AD  - Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Graham, Rondell P
AU  - Graham RP
AD  - Division of Laboratory Medicine and Anatomic Pathology, Mayo Clinic, Rochester, 
      MN, USA.
FAU - Gores, Gregory
AU  - Gores G
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
FAU - Smoot, Rory
AU  - Smoot R
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, USA. Electronic address: 
      Smoot.Rory@mayo.edu.
LA  - eng
PT  - Journal Article
DEP - 20220528
PL  - England
TA  - HPB (Oxford)
JT  - HPB : the official journal of the International Hepato Pancreato Biliary 
      Association
JID - 100900921
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
RN  - EC 2.7.10.1 (FGFR2 protein, human)
SB  - IM
MH  - Humans
MH  - Receptor, Fibroblast Growth Factor, Type 2/genetics/metabolism
MH  - *Bile Duct Neoplasms/genetics/surgery/metabolism
MH  - In Situ Hybridization, Fluorescence
MH  - Retrospective Studies
MH  - *Cholangiocarcinoma/genetics/surgery/metabolism
MH  - Gene Fusion
MH  - Bile Ducts, Intrahepatic/pathology
EDAT- 2022/06/20 06:00
MHDA- 2022/10/26 06:00
CRDT- 2022/06/19 22:17
PHST- 2021/12/30 00:00 [received]
PHST- 2022/03/17 00:00 [revised]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/06/20 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/06/19 22:17 [entrez]
AID - S1365-182X(22)01486-1 [pii]
AID - 10.1016/j.hpb.2022.05.1341 [doi]
PST - ppublish
SO  - HPB (Oxford). 2022 Oct;24(10):1748-1756. doi: 10.1016/j.hpb.2022.05.1341. Epub 
      2022 May 28.